Eos Management L.P. Buys Shares of 4,206 Charles River Laboratories International, Inc. $CRL

Eos Management L.P. bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, Holdings Channel reports. The institutional investor bought 4,206 shares of the medical research company’s stock, valued at approximately $839,000.

Other hedge funds have also made changes to their positions in the company. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $26,000. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the period. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at approximately $42,000. Sfam LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth approximately $43,000. Finally, Activest Wealth Management lifted its position in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

CRL stock opened at $185.17 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of -49.25, a P/E/G ratio of 2.12 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $228.88. The firm has a 50 day moving average of $174.82 and a two-hundred day moving average of $182.71.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Weiss Ratings cut shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Evercore reiterated an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.